Persistent thrombocytosis in patients with cancer needs workup because it can be linked to essential thrombocytosis. The management should be individualized to start treatment for low-risk essential thrombocytosis due to the combined risk of thrombosis.
Keywords: breast cancer; calreticulin; essential thrombocythemia; invasive ductal carcinoma; thrombocythemia.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.